CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 215 enrolled
Drug / intervention
Endotak Reliance Gdevice
Likely dose
Endotak Reliance G defibrillation lead placed in right ventricleAI-extracted
Key inclusion· 1
  • ✓Patients with ICD indication according to current Guidelines
Key exclusion· 3
  • ✕Indication for cardiac resynchronisation therapy
  • ✕Absence of spontaneous ventricular rhythm
  • ✕Pacemaker dependency

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00180297
NCT00180297N/ACompleted
CompareCT.gov

Evaluation of the Success Rate and the Clinical Evolution of a Ventricular Lead Implanted in the Septum Versus the Right Ventricular Apex.

Boston Scientific Corporation·interventional·Posted Sep 16, 2005·Updated Oct 14, 2021

In Brief

A clinical study evaluating Endotak Reliance G for Ventricular Tachycardia and Ventricular Fibrillation. Completed, enrolled 215 participants across 18 sites.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of the implant of a ICD lead of defibrillation in the septum of the right ventricle

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVentricular Tachycardia, Ventricular Fibrillation
CountriesFrance
CollaboratorsGuidant Corporation

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartApr 1, 2005
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 20.8 years ago

Interventions

Endotak Reliance Gdevice

Reliance G is a defibrillation lead to be placed in the right ventricle.